The marketing authorisations granted to Lupin Healthcare and Zentiva Pharma specifically apply to patients weighing at least 40kg.
The number of people living with a diagnosed HIV infection and accessing care in England rose from 91,368 in 2021 to 94,397 in 2022.
Merck & Co’s – known as MSD outside the US and Canada – Isentress (raltegravir) is an antiretroviral drug licensed for use in HIV patients.
Its active ingredient, raltegravir, stops the HIV integrase enzyme, which enables multiplication of the virus in cells within the body, from functioning. When used with other medicines, it can decrease the amount of HIV in patients’ blood and increase their CD4-cell count, which plays a vital role in maintaining a healthy immune system.
The recommended dosage for the medicine, which must be used in combination with other HIV drugs, is 1,200mg as two 600mg tablets taken orally once daily.
The MHRA’s decision on the raltegravir generics was supported by evidence from studies of healthy volunteers, which demonstrated that they were bioequivalent to Isentress, meaning their benefits and possible side effects are considered to be the same.
Shirley Hopper, MHRA deputy director of innovative medicines, said: “Ensuring timely access to generic medicines is a key priority for us.
“Appropriate data has been provided to assure us that these medicines are the same as, and considered interchangeable with an already licensed reference medicine…”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.